Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Specific immunotherapy with recombinant birch pollen allergen rBet v1-FV

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Birch Pollen Allergy Hypersensitivity Immune System Diseases

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Allergopharma GmbH & Co. KG

Reinbek, 21465, Germany

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Positive RAST result to birch pollen
Positive Skin Prick Test reaction to birch pollen
positive nasal provocation test result to birch pollen extract

Exclusion criteria

serious chronic diseases
other relevant seasonal allergies

Treatment and study plan

Recombinant birch pollen

Biological

Sponsors and collaborators

Lead sponsor

Allergopharma GmbH & Co. KG

Industry

Registry information

Official study title

A Bicentre Open Label Randomised Pilot Study for Proof of Safety and Efficacy of Immunotherapy With an Aluminium Hydroxide-adsorbed Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1-FV Versus a Depot Extract of Natural Birch Allergen

Important dates

Study start: 2003
Primary completion: 2004
Study completion: 2005
First posted: Dec 19, 2005
Registry last updated: Mar 4, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed